Form 4: Stoke Therapeutics Director Jennifer Burstein Granted Stock Options

Stoke Therapeutics, Inc. Director Jennifer Burstein was granted 29,747 stock options with an exercise price of $10.90, vesting by June 2026.

Summary

• Jennifer Burstein, a Director at Stoke Therapeutics, Inc. (STOK), was granted stock options as reported in a Form 4 filing.
• The grant consists of 29,747 Director Stock Options, representing a right to buy common stock.
• The exercise price for these options is $10.90 per share.
• The options are set to expire on June 2, 2035.
• The options will vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent on Ms. Burstein's continued service to the issuer.

Sentiment

Score: 7

Explanation: The document reports a routine grant of stock options to a director, which is a positive for aligning management incentives with shareholder interests, but does not contain information on company performance or strategic shifts, thus leaning slightly positive due to governance alignment.

Positives

• The grant of 29,747 stock options to Director Jennifer Burstein aligns her financial interests with those of the company's shareholders, promoting long-term value creation.
• The options have a long expiration date of June 2, 2035, providing a sustained incentive for the director's continued engagement and performance.

Future Outlook

The granted stock options are scheduled to vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent on the reporting person's continued service to the issuer.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aligning director incentives with long-term company performance and shareholder value. This type of compensation is standard for publicly traded companies to attract and retain qualified board members.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice, comparable to equity incentive plans seen across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, which provides for full vesting by a specific date or the next annual meeting, is typical for director equity awards, designed to ensure continued oversight and commitment.

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, which is a standard form of equity-based compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying a portion of compensation to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The options are subject to vesting conditions, with full vesting expected by June 3, 2026, or the next annual meeting, contingent on continued service.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, stock options, director compensation, insider transaction, equity grant